Last updated: April 26, 2026
Who Supplies Steglatro (ertugliflozin) for Brand Production and Distribution?
Steglatro is the brand name for ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The practical “supplier” question in pharma breaks into two tracks: (1) brand-owner commercialization and manufacturing network and (2) upstream chemical and finished-dose sourcing. Public records typically identify the brand holder and the listed manufacturers and sites used for regulatory supply, then map downstream distributors.
Who is the brand owner and commercialization supplier for Steglatro?
Merck Sharp & Dohme LLC (Merck) is the marketing authorization holder for Steglatro in the US and the entity that controls commercialization, regulatory filings, and contracted manufacturing supply for the brand.
| Role in supply chain |
Entity |
Scope |
| Brand owner / marketing authorization holder |
Merck Sharp & Dohme LLC |
US commercialization and regulatory control for Steglatro |
| Product name |
Steglatro |
Ertugliflozin |
Implication for “supplier”: When buyers ask “who supplies Steglatro,” the controlling answer for availability, contractual supply, and pharmacovigilance is the brand owner (Merck).
Which manufacturing supply sites are publicly identified for Steglatro?
Finished-dose manufacturers for Steglatro are typically disclosed through regulatory labeling and drug product listings (for example, US labeling and FDA product listings) and through public drug listing systems. Those records specify the manufacturing site(s) that produce the dosage form(s) sold under the brand.
But no complete, source-backed list of Steglatro manufacturing sites can be provided here because the request is not bounded by a geography (US vs EU vs other markets) and no concrete source excerpts are available in the prompt to support a definitive supplier roster.
What suppliers exist across the Steglatro supply chain?
1) Finished-dose manufacturers (drug product supply)
These are the sites that make the tablet strength(s) and package finished product under the brand label. Their identifiers normally appear in regulatory product listings and labeling.
Supplier type: contract manufacturing organizations (CMOs) or Merck-owned manufacturing sites, depending on site and country.
What matters for buyers/investors: batch release responsibility, packaging configurations, line capacity, and contingency supply.
2) Active pharmaceutical ingredient (API) and intermediate suppliers
Ertugliflozin API supply is sourced from specialized chemical manufacturing networks that produce the drug substance and key intermediates.
What matters: raw material availability, control strategy for impurities, and supply continuity for critical intermediates.
3) Packaging and distribution partners
For brand distribution, the “supplier” experience often maps to logistics and warehousing partners and regional wholesalers, but these vary by country and contract structure.
What matters: cold-chain requirements (if any), distribution lanes, and importation responsibility in each market.
Where “supplier” answers usually land in pharma purchasing
In pharma supply agreements, the counterparty typically falls into one of these forms:
| Procurement question |
Typical contract counterparty |
| “Who provides the product to market (brand availability)?” |
Brand owner (Merck) |
| “Who manufactures the tablets sold under Steglatro?” |
Listed drug product manufacturer(s) on regulatory listings |
| “Who supplies the API?” |
API manufacturer(s) disclosed in regulatory filings or procurement catalogs (country- and system-dependent) |
| “Who ships to wholesalers/pharmacies?” |
Regional distribution and logistics partners tied to the market |
For Steglatro specifically, the only fully supportable “supplier” identity from the provided material is the brand owner: Merck Sharp & Dohme LLC.
Steglatro supplier map (what can be stated without additional sourced site lists)
Brand commercialization supplier
Manufacturing and upstream supplier roster
- Not determinable from the information available in the prompt at the required level of specificity (site names, countries, and named suppliers for API and intermediates).
Key Takeaways
- Merck Sharp & Dohme LLC is the controlling supplier for Steglatro commercialization and regulatory stewardship in the US.
- A definitive list of drug product manufacturing sites and API/intermediate suppliers is not available in the provided input and cannot be accurately enumerated without source-backed site and supplier identifiers.
FAQs
1) Who is the supplier of Steglatro to the market?
Merck Sharp & Dohme LLC is the brand owner and the practical commercial supplier.
2) Is Steglatro manufactured by Merck-owned sites or contract manufacturers?
Both models exist in pharma supply chains, but a specific Steglatro site list is not provided in the input here.
3) Who supplies the ertugliflozin API for Steglatro?
The API supply network exists upstream, but the specific supplier names are not included in the provided information.
4) Do suppliers differ by country for Steglatro?
Yes. Manufacturing, labeling, and distribution partners commonly vary by market.
5) Where do I find the official manufacturer and site information for Steglatro?
Typically via regulatory product listings and the drug label’s manufacturer information for the relevant country.
References
[1] Merck Sharp & Dohme LLC. Steglatro (ertugliflozin) product information (brand and regulatory stewardship).
